JP2006508665A5 - - Google Patents

Download PDF

Info

Publication number
JP2006508665A5
JP2006508665A5 JP2004557611A JP2004557611A JP2006508665A5 JP 2006508665 A5 JP2006508665 A5 JP 2006508665A5 JP 2004557611 A JP2004557611 A JP 2004557611A JP 2004557611 A JP2004557611 A JP 2004557611A JP 2006508665 A5 JP2006508665 A5 JP 2006508665A5
Authority
JP
Japan
Prior art keywords
butyrylcholinesterase
butyrylcholinesterase variant
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004557611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508665A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/038684 external-priority patent/WO2004050041A2/en
Publication of JP2006508665A publication Critical patent/JP2006508665A/ja
Publication of JP2006508665A5 publication Critical patent/JP2006508665A5/ja
Pending legal-status Critical Current

Links

JP2004557611A 2002-12-04 2003-12-04 化学療法剤の活性を変化させるブチリルコリンエステラーゼ変異体 Pending JP2006508665A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31066602A 2002-12-04 2002-12-04
PCT/US2003/038684 WO2004050041A2 (en) 2002-12-04 2003-12-04 Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents

Publications (2)

Publication Number Publication Date
JP2006508665A JP2006508665A (ja) 2006-03-16
JP2006508665A5 true JP2006508665A5 (https=) 2007-02-01

Family

ID=32468084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004557611A Pending JP2006508665A (ja) 2002-12-04 2003-12-04 化学療法剤の活性を変化させるブチリルコリンエステラーゼ変異体

Country Status (9)

Country Link
US (1) US20080213281A1 (https=)
EP (1) EP1581253A4 (https=)
JP (1) JP2006508665A (https=)
CN (1) CN100341568C (https=)
AU (1) AU2003298920A1 (https=)
BR (1) BR0316865A (https=)
CA (1) CA2507626A1 (https=)
MX (1) MXPA05005996A (https=)
WO (1) WO2004050041A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989261B2 (en) * 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US20090208480A1 (en) * 2006-08-04 2009-08-20 Yue Huang Long half-life recombinant butyrylcholinesterase
US20100008978A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Nanoparticles effective for internalization into cells
US20100009390A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
CA2723821C (en) * 2008-05-16 2017-05-02 Nektar Therapeutics Conjugates of a cholinesterase moiety and a polymer
JP2013526840A (ja) 2009-12-21 2013-06-27 ファーマシーネ，インコーポレイテッド 組み換えブチリルコリンエステラーゼおよびその切断型
CN103898101B (zh) * 2012-12-27 2017-08-08 上海桀蒙生物技术有限公司 利用转基因动物乳腺生物平台大规模生产重组人丁酰胆碱酯酶的方法
CN104630177A (zh) * 2013-11-08 2015-05-20 中国农业大学 一种利用人丁酰胆碱酯酶迷你基因在乳腺中表达重组人丁酰胆碱脂酶的方法
US10301609B2 (en) 2014-04-29 2019-05-28 Mayo Foundation For Medical Education And Research Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin
WO2018053216A1 (en) * 2016-09-15 2018-03-22 Mayo Foundation For Medical Education And Research Methods and materials for using butyrylcholinesterases to treat cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378576B1 (en) * 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264563A (en) * 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5506125A (en) * 1993-12-22 1996-04-09 Agracetus, Inc. Gene delivery instrument with replaceable cartridges
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5656465A (en) * 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US6001625A (en) * 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
CA2330829C (en) * 1998-06-16 2011-08-02 Variagenics, Inc. Methods for treating a neurological disease by determining bche genotype
CN1331339A (zh) * 2000-06-26 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人dna拓扑异构酶i11.44和编码这种多肽的多核苷酸
US7070973B2 (en) * 2000-12-26 2006-07-04 Board Of Regents Of The University Of Nebraska Butyrylcholinesterase variants and methods of use
WO2002064796A2 (en) * 2000-12-26 2002-08-22 Applied Molecular Evolution, Inc. Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use
US20030153062A1 (en) * 2001-12-20 2003-08-14 Watkins Jeffry D. Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US7049121B2 (en) * 2001-12-20 2006-05-23 Applied Molecular Evolution Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US6989261B2 (en) * 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use

Similar Documents

Publication Publication Date Title
Kroutil et al. Exonucleolytic proofreading during replication of repetitive DNA
KR102761827B1 (ko) 타입 vi-b crispr 효소 및 시스템
CN106103699B (zh) 体细胞单倍体人类细胞系
Xue et al. Improved bioethanol production using CRISPR/Cas9 to disrupt the ADH2 gene in Saccharomyces cerevisiae
JP2006508665A5 (https=)
JPH07502898A (ja) 酵素ｒｎａ分子
JP2002535994A5 (https=)
CA2306188A1 (en) A novel method for the integration of foreign dna into eukaryotic genomes
CN103911376A (zh) CRISPR-Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA
CA2963820A1 (en) Methods for improving crispr/cas-mediated genome-editing
WO2023102329A2 (en) Effector proteins and uses thereof
CN107513538A (zh) 基因敲除方法
AU2002304258A1 (en) Method for the stable inversion of dna sequence by site-specific recombination and dna vectors and transgenic cells thereof
WO2023092132A1 (en) Effector proteins and uses thereof
US20230332218A1 (en) Casy programmable nucleases and rna component systems
CN107686842A (zh) 一种靶多核苷酸编辑方法及其应用
JP7769691B2 (ja) 新規の改良された塩基編集または編集用融合タンパク質およびその用途
Wang et al. Cre‐mediated transgene integration in Chinese hamster ovary cells using minicircle DNA vectors
US20240110163A1 (en) Crispr-associated based-editing of the complementary strand
Zheng et al. Sequence Context‐Agnostic TadA‐Derived Cytosine Base Editors for Genome‐Wide Editing in Zebrafish
JP7109009B2 (ja) 遺伝子ノックアウト方法
US20230295666A1 (en) Super-enchancers for recombinant gene expression in cho cells
CN115896149A (zh) 运动发酵单胞菌基因编辑质粒、试剂盒、方法及应用
EP4230737A1 (en) Novel enhanced base editing or revising fusion protein and use thereof
WO2022187278A1 (en) Nucleic acid detection and analysis systems